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Variant Creutzfeldt-Jakob disease (vCJD) may be
transmissible by blood. To prevent secondary transmission
through blood components, several countries have started
to exclude as donors persons who have received a blood
transfusion. We investigated the effectiveness of this meas-
ure by using a dynamic age-structured model. It is the first
such model based on epidemiologic data: 1) blood donor
activities, 2) a case-control study on CJD, 3) age distribu-
tion of recipients, and 4) death of recipients of blood trans-
fusions. The model predicts that an infection like vCJD,
which has been introduced into the population by the ali-
mentary route, could not become endemic by transfusion
alone and that only <1% of cases would be avoided by
excluding from blood donation those persons who have
received a transfusion.
R
ecent studies of variant Creutzfeldt-Jakob disease
(vCJD) indicate that this disease is transmissible by
blood. One case of probable transfusion-transmitted vCJD
infection has been reported, and 1 case of subclinical infec-
tion has been detected (1,2). On February 9, 2006, a third
case was announced by the UK Health Protection Agency
(www.hpa.org.uk/hpa/news/articles/press_releases/
2006/060209_cjd.htm). Each of the 3 patients had received
a blood transfusion from a donor who subsequently devel-
oped clinical vCJD, which indicates that transfusion
caused the infection. However, a policy to exclude poten-
tial donors who had received a transfusion would not have
prevented at least the first 2 cases because the correspon-
ding donors had not received any blood transfusion.
Diagnostic tools to detect prions in blood are under devel-
opment (3), but no routine test for the presence of the
infectious agents of vCJD is available. Therefore, the ques-
tions arise as to whether an infection like vCJD could
become endemic through blood donation alone and to what
extent exclusion of potential donors with a history of trans-
fusion would influence the transmission of such an infec-
tion (i.e., how many deaths due to the infection could be
prevented?). The following mathematical model is the
first to address these questions on the basis of epidemio-
logic data and realistic and epidemiologically justified
assumptions.
Methods
Model Structure
Figure 1A shows the transitions of a person through
the basic states of potential donor activities and receipt of
blood transfusion. After birth a person is in the state of not
having received any transfusion and not yet being an active
donor (S00). The first index refers to the person’s state as a
transfusion recipient; the second index, to the person’s sta-
tus as a donor. Persons in state S00 can change to state S01
by becoming a donor or to state S100 or S101 by receiving a
blood transfusion. The third index indicates whether a per-
son with a transfusion history can actually be identified
and excluded from donating blood (deferred) (index 1) or
not (index 0). The states S111 and S110 can be reached by
either transfusion recipients who start donating blood or
active donors who receive a blood transfusion. Blood
donors who become inactive are transferred into the states
of ex-donors S02 and S12, depending on their transfusion
history. Ex-donors can also become transfusion recipients;
i.e., they are transferred from S02 to S12. Donor exclusion
transfers a certain proportion of transfusion recipients into
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shows the transitions to the corresponding infected states.
Table 1 provides a list of all input parameters together with
descriptions and sources. The details of the model with all
the numerical parameter estimates and the equations are
given in the online Appendix (available from www.cdc.
gov/ncidod/EID/13/1/89-app.htm). The computer program
is available upon request. This article summarizes the
major features of the model, the data sources, and the esti-
mation of the model parameters.
Demography
To simplify the model, we did not attempt to describe
the demographics of the population during the next 150
years. Doing so would involve predicting changes in rates
of birth, death, and immigration. It is assumed that in the
absence of infection, the population is demographically
stationary. We assumed a constant inflow of newborns and
an age-specific death rate. The latter was estimated as a
weighted mean of the age-specific female and male death
rates. Because this study was initiated in Germany, we
used the corresponding demographic data. To start the sim-
ulation in a demographically stationary state, the model
was run for 100 years without infection. Thus, the age dis-
tribution of the population was identical to the life table of
Germany 2002/2004 averaged over both sexes (www.
destatis.de/download/d/bevoe/sterbet04.xls). 
Modeling Blood Donors
Blood donors in Germany are >18 and <68 years of
age. The rates for becoming a new donor and terminating
the period as an active donor are age dependent. The cor-
responding parameters were estimated by using data from
262,071 donors registered with the German Red Cross
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Figure 1. A) States and transitions for the
model of blood transfusion in the absence of
an infection. B) Routes of infection. The
arrows representing deaths out of all states
are omitted. Paths of donor exclusion are
plotted by dotted arrows. S00, nonrecipients
who do not donate; S01, nonrecipients who
donate; S02, nonrecipients who are excluded
from donating; S100, recipients who do not
donate; S101, recipients who become exclud-
ed from donating; S110, recipients who donate;
S111, recipients who become excluded from
donating; S12, recipients who are excluded
from donating. Indices replaced by a dot
(panel B) represent all other possible states
(e.g., S0• represents S00, S01, or S02).(DRK) Blood Service West in Hagen, Germany, including
age, sex, age at first donation, number of donations, and
date of last donation.
The age-specific prevalence of active donors peaks at
≈24 years of age and subsequently declines monotonical-
ly to zero by age 68. The overall prevalence in the popu-
lation is 3%, i.e., 2.4 million donors in a population of
≈80 million.
Modeling Transfusion Recipients 
The model takes into account that persons may
receive >1 transfusion throughout their lifetime, but it does
not track the number of transfusions received per person.
Persons with >1 transfusion continue to be at risk for infec-
tion from further transfusions. The age-specific risk of
receiving a transfusion was estimated from data for all
patients hospitalized at the University Hospital in Essen
during March 2003. Of 4,867 patients, 1,343 (27.6%)
received >1 transfusion. The number of persons receiving
a blood transfusion in each 5-year age group was divided
by the corresponding number of persons in the general
population. The observed rates were fitted with a simple
model that assumes initially an exponential decline and
subsequently a unimodal peak, which is proportional to the
density function of the normal distribution. These age-spe-
cific ratios were properly scaled to balance the yearly num-
ber of transfusions per capita. To limit the complexity of
the model, we did not take into account persons in sub-
groups, such as those with hemophilia, who obtain blood
products from pools of donors. Because for medical rea-
sons these subgroups are excluded from donating blood,
they cannot contribute to persistence of the infection.
Independence of Receiving and Donating Blood
The events of receiving a blood transfusion and of
donating blood are assumed to be independent of each
other. This assumption is supported by the results of a
case-control study of potential risk factors for CJD, which
was coordinated by the Clinical Surveillance Centre for
CJD, Department of Neurology in Göttingen, Germany
(7). Table 2 shows the joint distribution for the control
group of having received and donated blood. According to
the Fisher exact test, the p value for the hypothesis of no
association is 0.43.
Heterogeneity in the risk of receiving a blood transfu-
sion is modeled by the assumption that only a proportion
of the population are at risk, whereas the remaining pro-
portion never receives a transfusion. This assumption was
introduced to be consistent with data from the case-control
study, in which ≈18% of the population reported having
ever received a blood transfusion. Without this assump-
tion, the model would predict that eventually 100% of a
cohort would receive a blood transfusion because the aver-
age annual risk of receiving a blood transfusion is about
5%, i.e., ≈4 million in a population of 80 million.
Modeling Transfusion-associated Death Rates
The transfusion-associated death rate has been
described in detail by Wallis et al. (4). Agood fit to the data
assumes that at all ages a certain proportion of transfusion
recipients have a higher rate of dying and the remaining
proportion has a survival rate that corresponds to that of
persons of the same age group in the general population.
This age-dependent proportion of transfusion recipients
with an increased risk for death is described by a general-
ized logistic function with a positive value at birth and an
asymptote <100% for old age. The transfusion-associated
death rate increases linearly with age. The increased death
rate appears to be concentrated in the first 2 years after a
transfusion. Wallis et al. report that 2,888 patients were
observed as long as 7.4 years after transfusions received in
June 1994 (4). The sex-specific rates were averaged for the
simulation model.
Modeling the Infection
Usually the incubation period refers to the time
between the infection and disease. In the context of CJD,
however, disease can refer to onset, diagnosis, or death.
Like Bacchetti, we also focused on death rates (8–10).
The incubation period is assumed to be gamma distributed
with a mean duration of 16 years and a standard deviation
of 4 years, which conforms to estimates of Valleron et al.
and Ghani et al. (5,6). Because of great uncertainty about
the length of the incubation time, we also considered a
much higher value of 50 years in the absence of the com-
peting risk for death. The coefficient of variation is
assumed to be the same, such that the standard deviation
is 12.5 years. Because of competing risks, the actual
sojourn in the incubation period is 15.3 for an incubation
period of 16 years and 34.0 years for an incubation period
of 50 years. The proportions of infected persons who
would die with disease symptoms are 79% and 37% for
the incubation periods of 16 and 50 years, respectively.
This means that for an incubation time of 50 years, near-
ly two thirds would die without disease symptoms.
Hereafter we refer to these values of 15 and 50 years as
short and long incubation periods.
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Initially, the infection is introduced into the population by
the alimentary route. In the United Kingdom the number of
infected animals entering the food supply peaked in 1989;
most were concentrated within a period of 10 years (11),
which we take as the assumed period of alimentary infec-
tion. After this period, this mode of transmission was inter-
rupted so that further transmissions are possible only
through blood transfusions.
A study to detect the presence of abnormal prion pro-
tein in appendix and tonsil tissues has suggested a preva-
lence of 235 infections per million in the United Kingdom
(12). We arbitrarily assumed the prevalence of infections
in Germany to be ≈1 order of magnitude lower, yielding a
cumulative incidence of 25 per million, which was the
value used for the simulations.
We made 2 contrasting assumptions about the infec-
tivity of blood preparations and evaluated the results of
these 2 simulations: each transfusion (100% infectivity) or
no blood transfusion (0% infectivity) from an infected
donor leads to infection of the recipient. In the model the
infection probability (probability of receiving blood from
an infected donor) is proportional to the proportion of
infected donors among all donors. Thus, we can calculate
the number of infections from blood transfusions com-
pared with the number of infections from alimentary trans-
mission alone.
Modeling Donor Exclusion
The model distinguishes between persons with and
without transfusion history, termed recipients and nonre-
cipients; these terms are applied to persons whether they
have or have not donated blood. The model allows recipi-
ents to be excluded from donating blood. In modeling the
exclusion of recipients, we took into account that this
measure may be imperfect and that a certain proportion of
recipients may not be excluded.
Results
For the parameter estimates obtained from the sources
described above, the infection cannot become endemic
(Figure 2). If we assume no further spread through blood
transfusions after 10 years of infections by the alimentary
route, the maximum prevalence reached is ≈1,860 (1,434
for nonrecipients plus 426 for recipients) because some of
the infected persons die of other causes during the incuba-
tion period. If transmission is assumed to be possible
through blood transfusions (100% infectivity), then the
maximum prevalence among recipients is increased by
≈78 infections after 4 more years for the short incubation
period and by 193 infections after 23 more years for the
long incubation period.
We assumed that donor exclusion is implemented
immediately at the beginning of the alimentary infection
risk period, which reduced the original number of 2.55
million donors by ≈20% to a value of 2.05 million donors.
Because the model does not account for the stock of blood
donations, this reduction in the number of donors must be
compensated for with an increased rate of donations per
donor to satisfy the demand; i.e., the average number of
donations would have to increase from 1.6 to 2 per donor
per year. Figure 2Ashows that donor exclusion has almost
no effect when the incubation period is assumed to be 16
years. The absolute prevalence (i.e., the actual number of
infected persons) differs at most by 9. For a long incuba-
tion, differences are visible (59 persons at most) but small
in view of the long time intervals and the size of the total
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Figure 2. Absolute prevalence of infection for an incubation period
of 16 (A) and 50 (B) years, for nonrecipients of blood transfusion
(solid, black), recipients under the assumption of no infectivity
(dashed, gray), of 100% infectivity without donor exclusion (dotted,
black), and 100% infectivity with donor exclusion (solid, gray). The
prevalence declines after the alimentary route of transmission is
interrupted, i.e., after 10 years. Prevalence differs only slightly if
the infection probability of a transfusion from an infected donor is
increased from 0% to 100%. Donor exclusion produces negligible
reductions. population (Figure 2B). The reason for these small differ-
ences is described below.
The cumulative numbers of deaths from the infection
are given in Table 3. The numbers are considerably small-
er for the long than for the short incubation period because
a long incubation period implies more deaths from other
causes. The numbers are given separately for cases in
patients with and without a history of blood transfusion.
The route of infection for nonrecipients is alimentary only,
whereas the route of infection for recipients is unclear. If
we compare the simulations at 100% and 0% infectivity of
blood transfusions, we observe 172 and 224 additional
cases for the short and the long incubation periods, respec-
tively. These numbers represent 11% of 1,557 and 31% of
725 cases, which would be expected for 0% infectivity for
the short and long incubations periods, respectively. For
the short incubation period we expect a higher absolute
number of alimentary cases but a smaller proportion of
transfusion cases than for the long incubation period. The
exclusion of donors would prevent only 15 and 50 cases,
i.e., ≈15 (0.9%) of 1,729 and 50 (5%) of 949, respectively,
at the end of the epidemic. The epidemic lasts for ≈50 or
≈150 years for the short and the long incubation periods,
respectively. 
The predicted yearly incidence of deaths due to vCJD,
separated by transfusion history, is shown in Figure 3. The
yearly peak incidence of total deaths would be 128 and 29
for the short and the long incubation periods at 23 and 51
years after the beginning of the epidemic, respectively. For
0% infectivity the peak incidence would be only 5 and 3
cases less for the short and long incubation periods,
respectively, which implies that the exclusion of donors
with a transfusion history does not effectively prevent
infection.
Figure 4 shows the predicted yearly incidence of
deaths according to the route of infection. The time lags
between the peaks of deaths due to alimentary infection
and due to transfusion clearly differ and are 9 and 20 years
for short and long incubation periods, respectively.
Finally, we considered the absolute prevalence of
infected donors according to their history of blood transfu-
sion (Figure 5). Most infected donors do not have a trans-
fusion history, which explains the negligible effect of a
policy excluding transfusion recipients from donation. 
To determine whether the same model could also pre-
dict transition into a positive endemic equilibrium of the
infection, we made the unrealistic assumptions that the
rates of donor recruitment and donor loss are constant
between the ages of 18 and 67 and that the rate of receiv-
ing a blood transfusion is constant throughout life. Then
the model showed an extremely long time (>2,000 years)
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Figure 3. The yearly incidence of deaths for an incubation period
of 16 (A) and 50 (B) years. The black curves show nonrecipients
of blood transfusion who were infected only by the alimentary
route. These curves are independent of the infection probability
and the rate of donor exclusion. The lower 3 curves represent the
deaths of recipients originating from 0% infectivity of blood trans-
fusions (dashed gray), 100% infectivity without donor exclusion
(solid gray), and 100% infectivity of blood transfusions with donor
exclusion (dotted black, almost indistinguishable from solid gray
line in A). The differences between the solid and dashed gray
curves represent the cases due to blood transfusion.before positive equilibrium would be reached (results not
shown).
Discussion
Our model is the first attempt to describe in a realistic
way the transmission of infections through blood transfu-
sions. In 1994, Velasco-Hernández proposed a model for
the spread of Chagas disease by vectors and blood transfu-
sion (13).His model was used by Roberts and Heesterbeek
to introduce their new concept to estimate the effort to
eradicate an infectious disease (14). Huang and Villasana
included transmission through blood transfusion in an
AIDS model (15).All these models have in common what
Inaba and Sekine state about their extension of Velasco-
Hernández’s Chagas model: “…here we assume that blood
donors are randomly chosen from the total population, and
so there is no screening and the recipients of blood dona-
tions are donating blood themselves at the same rate as
anybody else. This is an unrealistic assumption, but we
will use it.” (16). These models implicitly describe trans-
mission through blood transfusion exactly like person-to-
person transmission by droplet infections.
The key innovation in our model is the simultaneous
incorporation of 6 functions that all depend explicitly on
the age of a person: 1) natural death rate, 2) rate of receiv-
ing a blood transfusion, 3) rates of donor recruitment, 4)
donor loss, 5) death rate associated with transfusions, and
6) proportion of transfusion recipients at increased risk for
death. The age-dependent effects of these processes cannot
be ignored. Peak ages of donor activity (≈22 years) and of
receiving a blood transfusion (≈70 years) are quite distinct
and ≈50 years apart. This age pattern does not favor the
spread of infection by blood transfusion. Another factor
that acts against the infection becoming endemic is the
transfusion-associated death rate. The good quality of the
follow-up data of nearly 3,000 patients helped to incorpo-
rate realistic assumptions about the survival probabilities
of transfusion recipients (4).The only data available about
the joint distribution of blood donor activity and history of
a blood transfusion was the CJD case-control study per-
formed in Göttingen, Germany (7).
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Figure 4. Yearly incidence of deaths caused by alimentary trans-
mission (solid line) and by blood transfusion (dashed line).The 2
peaks differ by 9 and 20 years, depending on the incubation peri-
od: 16 (A) and 50 (B) years, respectively.
Figure 5. Absolute prevalence of infected donors for an incubation
period of 16 (A) and 50 (B) years. The solid black curves show the
infected donors without transfusion history. These curves are iden-
tical for 0% and 100% infectivity and are independent of donor
exclusion. The gray curves show infected donors with transfusion
history for 100% (solid) and 0% (dashed) infectivity, respectively,
without donor exclusion. The dotted black curves show the effect
of donor exclusion starting at the beginning of alimentary risk.
Most infected donors have no transfusion history and cannot,
therefore, be excluded from blood donation.The length of the incubation period plays a major role
in transmission dynamics and hence was subject to a sen-
sitivity analysis. The model does not account for possible
changes of infectivity during the incubation period. The
model represents a worst-case scenario because it assumes
100% infectivity throughout the period of infection. Even
under this extreme assumption, donor exclusion can pre-
vent only 0.9% (or 5%) of the expected deaths, assuming
the incubation period has a mean duration of 16 (or 50)
years. The main explanation for this surprising result is
that most infected donors have been infected by the ali-
mentary route and never received any blood transfusion
and, therefore, are not eligible for donor exclusion.
The present simulations have arbitrarily assumed a
cumulative incidence of alimentary infection, about 25 per
million (2,000 per 80 million). With pessimistic assump-
tions, the model predicts either 19.5 deaths per million for
the short incubation period or 9 deaths per million for the
long incubation period in the absence of spread through
blood transfusion. This corresponds to at least 9 (36%) of
25 deaths attributable to the infection, which is ≈2 orders
of magnitude higher than expected for vCJD in the United
Kingdom. As of July 2006, the number of vCJD cases in
the United Kingdom was 160. If we assume that the total
number of cases will be 200, then our assumption corre-
sponds to about 3.3 cases per million. Thus, at most, 1.4%
of infected persons would die from the infection (unless a
second wave of vCJD cases with a long incubation period
occurs). According to our model, 0.9% of the deaths could
be prevented by donor exclusion under the assumption of
the short incubation period. In absolute numbers this
would be ≈2 cases.
In France, the total number of vCJD cases recorded
through July 2006 is 18. Even under the assumption that
this number represents only 35% of the total number of
cases (17), the absolute expected number of prevented
cases would be <1. In 1998, France decided to exclude
donors with a transfusion history, primarily to reduce the
spread of viruses. The present model could be modified to
assess the effectiveness of excluding donors with transfu-
sion history for preventing emerging infections with differ-
ent modes of transmission and additional epidemiologic
states, e.g., latent or immune.
Our worst-case scenario assumptions of the epidemi-
ology might seem similar to the situation in the United
Kingdom. In Germany, no case of vCJD has been report-
ed, which indicates that the expected number of cases in
Germany is at least 2 orders of magnitude less than that in
the United Kingdom. This latter aspect was considered in
the interpretation of our model by a working group com-
missioned by the German Federal Minister of Health,
which recommended in April 2006 that persons with a
transfusion history not be excluded from donating blood
(18). Our analysis enables different countries to perform
their own risk assessment and choose a strategy according
to the absolute number of cases observed or expected.
The German CJD Surveillance study was supported by a
grant from the German Ministry of Health (Az 325-4471-02/15
to Inga Zerr and H. A. Kretzschmar). Helpful discussions about
previous versions of the model took place with the Working
Group Overall Blood Supply Strategy with regard to vCJD,
Germany (Chairman R. Seitz).
Dr Dietz is head of the Department of Medical Biometry at
the University of Tübingen, Germany. His main interest is the
application of mathematical models in the field of infectious
diseases, in particular malaria and other parasitic diseases.
References
1.  Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S,
Mackenzie J, et al. Possible transmission of variant Creutzfeldt-
Jakob disease by blood transfusion. Lancet. 2004;363:417–21. 
2.  Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical
vCJD after blood transfusion in a PRNP codon 129 heterozygous
patient. Lancet. 2004;364:527–9. 
3.  Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med.
2005;11:982–5. 
4.  Wallis JP, Wells AW, Matthews JN, Chapman CE. Long-term sur-
vival after blood transfusion: a population based study in the North
of England. Transfusion. 2004;44:1025–32. 
5.  Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidem-
ic size and incubation time based on age characteristics of vCJD in
the United Kingdom. Science. 2001;294:1726–8. 
6.  Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Updated
projections of future vCJD deaths in the UK. BMC Infect Dis.
2003;3:4. 
7.  Zerr I, Brandel JP, Masullo C, Wientjens D, de Silva R, Zeidler M,
et al. European surveillance on Creutzfeldt-Jakob disease: a case-
control study for medical risk factors. J Clin Epidemiol.
2000;53:747–54. 
8.  Bacchetti P. Unexamined assumptions in explorations of upper limit
for cases of variant Creutzfeldt-Jakob disease. Lancet.
2001;357:3–4. 
9.  Bacchetti P. Age and variant Creutzfeldt-Jakob disease. Emerg
Infect Dis. 2003;9:1611–2. 
10.  Bacchetti P. Uncertainty due to model choice in variant Creutzfeldt-
Jakob disease projections. Stat Med. 2005;24:83–93. 
11.  Collins SJ, Lawson VA, Masters CL. Transmissible spongiform
encephalopathies. Lancet. 2004;363:51–61. 
12.  Clarke P, Ghani AC. Projections of the future course of the primary
vCJD epidemic in the UK: inclusion of subclinical infection and the
possibility of wider genetic susceptibility. J R Soc Interface.
2004;2:19–31.
13.  Velasco-Hernandez JX. A model for Chagas disease involving
transmission by vectors and blood transfusion. Theor Popul Biol.
1994;46:1–31. 
14.  Roberts MG, Heesterbeek JA. A new method for estimating the
effort required to control an infectious disease. Proc R Soc Lond B
Biol Sci. 2003;270:1359–64. 
15.  Huang XC, Villasana M. An extension of the Kermack-McKendrick
model for AIDS epidemic. Journal of the Franklin
Institute–Engineering and Applied Mathematics. 2005;342:341–51.
Blood Transfusion and Variant Creutzfeldt-Jakob Disease
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 1, January 2007 9516.  Inaba H, Sekine H. A mathematical model for Chagas disease with
infection-age-dependent infectivity. Math Biosci. 2004;190:39–69. 
17.  Chadeau-Hyam M, Alperovitch A. Risk of variant Creutzfeldt-
Jakob disease in France. Int J Epidemiol. 2005;34:46–52.
18.  German Federal Ministry of Health Working Group. Overall blood
supply strategy with regard to variant Cruetzfeldt-Jakob disease
(vCJD). Transfusion Medicine and Hemotherapy. 2006;33(Suppl
2):1–39.
Address for correspondence: Klaus Dietz, Department of Medical
Biometry, University of Tübingen, Westbahnhofstr. 55, Tübingen,
Germany; email: klaus.dietz@uni-tuebingen.de
RESEARCH
96 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 1, January 2007
All material published in Emerging Infectious Diseases is in the
public domain and may be used and reprinted without special per-
mission; proper citation, however, is required.
Search